SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

June 2018 Autoimmune News

Rituximab for refractory rapidly progressive interstitial lung disease (RP–ILD) related to anti-MDA5 antibody–positive amyopathic dermatomyositis. Our results suggest that RTX may be a useful therapy for anti-MDA5 Ab-positive ADM associated with RP–ILD, although infection is the major risk. PubMed, Clin Rheumatol, 04/30/2018. (Also see Treatments for Dermatomyositis and Biologic Agents)

Atherosclerosis and autoimmunity: a growing relationship. Being armed with the mechanisms underlying autoimmunity in the etiopathogenesis of atherosclerosis in rheumatic autoimmune disorders and the shared etiologic pathway may result in substantial developing therapeutics for these patients. PubMed, Int J Rheum Dis, 04/19/2018. (Also see Cardiac (Heart) Involvement)

Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. As in adults with inclusion body myositis, patients with juvenile myositis with anti-NT5C1A autoantibodies have more severe disease. PubMed, Ann Rheum Dis, 2018 May;77(5):714-719. (Also see Dermatomyositis and Polymyositis)

Pain and emotion as predictive factors of interoception in fibromyalgia (FM). Pain–related affect and reactions in FM patients can reduce their interoceptive ability and our results help to better understand the integration between bodily signals and emotional processing in chronic pain. PubMed, J Pain Res, 2018 Apr 19;11:823-835. (Also see Fibromyalgia)

Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus (SLE). In this SLE cohort, the non–criteria aPL aD1 IgG and aPS-PT IgG performed differently. PubMed, Rheumatology (Oxford), 04/17/2018. (Also see Antibodies in Lupus)

Case Reports: Skin and mucous membranes' manifestations of dermatological diseases within the genital area in females. While analyzing the available scientific reports, the physician in charge must adjust therapeutic options individually, in the case of dermatological diseases within the female genital region. PubMed, Postepy Dermatol Alergol, 2018 Apr;35(2):199-203. (Also see Lichen Sclerosus et Atrophicus)

Therapeutic Applications of Mesenchymal Stem Cells (MSCs) for Systemic Lupus Erythematosus (SLE). The immuno–modulatory and regenerative characteristics of MSCs make them as one promising candidate for treating SLE. PubMed, Adv Exp Med Biol, 05/17/2018. (Also see Stem Cell Transplantation)

Early Diagnosis and Treatment of Rheumatoid Arthritis (RA). This article provides a current overview of our understanding of rheumatoid arthritis, with an emphasis on early diagnosis and approaches to treatment. PubMed, Prim Care, 2018 Jun;45(2):237-255. (Also see Rheumatoid Arthritis)

Pulsed electromagnetic field (PEMF) therapy in the treatment of pain and other symptoms in fibromyalgia: A randomized controlled study. This study demonstrated that low–energy PEMF therapy was not efficient in reducing pain and stiffness or in improving functioning in women with fibromyalgia. PubMed, Bioelectromagnetics, 04/30/2018. (Also see Fibromyalgia)

Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis (MS) Treatment. A receptor–selective modulation of TNFα signal pathways provides a novel therapeutic concept that might lead to new insights in MS pathology with major implications for its effective treatment. PubMed, Front Immunol, 2018 Apr 30;9:925. (Also see Multiple Sclerosis)

Go to Autoimmune News: May 2018

SCLERO.ORG was the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses from 1998 to 2021. It was a grassroots movement from the original Scleroderma from A to Z web site, which was founded by Shelley Ensz. We were a 501(c)(3) U.S.-based public charitable foundation. We closed this web site and our nonprofit agency in April 2021.

International Scleroderma Network (ISN)